Cargando…
In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication
INTRODUCTION: Letermovir (LMV) is used for prophylaxis of cytomegalovirus (CMV) reactivation and end-organ disease in adult CMV-seropositive allogeneic hematopoietic stem cell transplant recipients (allo-HSCT). In turn, sirolimus (SLM) which displays in vitro anti-CMV activity, is frequently employe...
Autores principales: | Giménez, Estela, Guerreiro, Manuel, Gozalbo-Rovira, Roberto, Aguilar, Cristobal, Albert, Eliseo, Piñana, José Luis, Solano, Carlos, Navarro, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586729/ https://www.ncbi.nlm.nih.gov/pubmed/37365797 http://dx.doi.org/10.37201/req/016.2023 |
Ejemplares similares
-
Letermovir for the compassionate therapeutic use of cytomegalovirus infection
por: Schubert, Lorenz, et al.
Publicado: (2020) -
Letermovir for cytomegalovirus prophylaxis
Publicado: (2019) -
Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft‐versus‐host disease prophylaxis
por: Hernani, Rafael, et al.
Publicado: (2021) -
Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients
por: Santos Bravo, Marta, et al.
Publicado: (2022) -
2648. Terminating the Troll of Transplantation: Letermovir for Cytomegalovirus Prophylaxis
por: Hedvat, Jason, et al.
Publicado: (2019)